Prime Medicine, Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Prime Medicine, Inc. (PRME) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$357.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-09.
Discontinued › Income Statement
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2023-03-09
- Prime Medicine, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2022-12-31 was $70.00K.
- Prime Medicine, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2022-09-30 was -$304.00K, a 1316.00% decline year-over-year.
- Prime Medicine, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2021-12-31 was -$18.00K.
- Prime Medicine, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2021-09-30 was $25.00K.
- Prime Medicine, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was -$357.00K.
- Prime Medicine, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2021 was -$27.00K.
- Prime Medicine, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2020 was $0.00.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2022-12-31 | $70.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$234.00K derived: sum of 2 quarters · filed 2023-03-09 | -$357.00K 10-K · filed 2023-03-09 | |
| 2022-09-30 | -$304.00K 10-Q · filed 2022-11-14 | -$427.00K 10-Q · filed 2022-11-14 | ||
| 2021-12-31 | -$18.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $7.00K derived: sum of 2 quarters · filed 2023-03-09 | -$27.00K 10-K · filed 2023-03-09 | |
| 2021-09-30 | $25.00K 10-Q · filed 2022-11-14 | -$9.00K 10-Q · filed 2022-11-14 | ||
| 2020-12-31 | $0.00 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |